董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Frank Fischer | 男 | Director | 79 | 40.89万美元 | 未持股 | 2020-12-31 |
| Greg Garfield | 男 | Director | 57 | 未披露 | 未持股 | 2020-12-31 |
| Nael Karim Kassar | 男 | Director | 41 | 未披露 | 未持股 | 2020-12-31 |
| Rakhi Kumar | 女 | Director | 41 | 未披露 | 未持股 | 2020-12-31 |
| Evan Norton | 男 | Director | 46 | 未披露 | 未持股 | 2020-12-31 |
| Renee Ryan | 女 | Director | 52 | 0.05万美元 | 未持股 | 2020-12-31 |
| Michael Favet | 男 | Director, President and Chief Executive Officer | 51 | 67.16万美元 | 未持股 | 2020-12-31 |
| Rishi Gupta | 男 | Director | 43 | 未披露 | 未持股 | 2020-12-31 |
| Joseph Lacob | 男 | Director | 64 | 未披露 | 未持股 | 2020-12-31 |
| Joseph S. Lacob | 男 | Director | 64 | 未披露 | 未持股 | 2020-12-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael Favet | 男 | Director, President and Chief Executive Officer | 51 | 67.16万美元 | 未持股 | 2020-12-31 |
| Martha Morrell | -- | Chief Medical Officer | 64 | 48.40万美元 | 未持股 | 2020-12-31 |
| Rebecca Kuhn | 女 | Chief Financial Officer and Vice President, Finance and Administration | 60 | 44.36万美元 | 未持股 | 2020-12-31 |
| Irina Ridley | 女 | General Counsel and Corporate Secretary | 35 | 未披露 | 未持股 | 2020-12-31 |
董事简历
中英对照 | 中文 | 英文- Frank Fischer
-
Frank Fischer，2012年10月起，担任本公司董事。他于2000年加入NeuroPace, Inc，这是神经系统疾病治疗设备的私营开发商，现为其总裁、首席执行官。1998年5月至1999年9月，他担任Heartport, Inc的总裁、首席执行官、董事，这是原心脏外科上市公司，在2001年被Johnson & Johnson收购。1987-1997，他担任Ventritex, Inc的总裁、首席执行官，这是一家上市公司，从事设计、开发、制造、销售用于治疗室性心动过速、心室颤动的植入式除颤器及相关产品，在1997年被St. Jude Medical收购。他目前是一些私营企业的董事。他在Rensselaer Polytechnic Institute获得机械工程学士学位、管理学硕士学位。
Frank Fischer,has more than 40 years of senior management experience in the medical device industry. He co-founded NeuroPace in December 1997, led the company as its President and Chief Executive Officer from January 2000 through July 2019, served on its Board of Directors since inception and is currently Chairman of the Board. Prior to joining NeuroPace, Mr. Fischer was President and Chief Executive Officer of Heartport, Inc., a cardiac surgery company, from May 1998 until September 1999 and served on Heartport's Board of Directors. Previously, Mr. Fischer was President and Chief Executive Officer and a director of Ventritex, Inc., a company that pioneered implantable cardiac defibrillators, from July 1987 until the sale of the company to St. Jude Medical, Inc. in 1997. Before joining Ventritex, he held various management positions at Cordis Corporation from 1977 to 1987 in the cardiac and neurosurgical device areas, serving most recently as President of the Implantable Products Division. Currently he is a member of the Board of Directors of Nevro, Inc., the Board of Trustees of both Rensselaer Polytechnic Institute and Babson College as well as the Board of Directors of the Epilepsy Foundation of America. Mr. Fischer holds B.S.M.E. and M.S. in Management degrees from Rensselaer Polytechnic Institute. - Frank Fischer，2012年10月起，担任本公司董事。他于2000年加入NeuroPace, Inc，这是神经系统疾病治疗设备的私营开发商，现为其总裁、首席执行官。1998年5月至1999年9月，他担任Heartport, Inc的总裁、首席执行官、董事，这是原心脏外科上市公司，在2001年被Johnson & Johnson收购。1987-1997，他担任Ventritex, Inc的总裁、首席执行官，这是一家上市公司，从事设计、开发、制造、销售用于治疗室性心动过速、心室颤动的植入式除颤器及相关产品，在1997年被St. Jude Medical收购。他目前是一些私营企业的董事。他在Rensselaer Polytechnic Institute获得机械工程学士学位、管理学硕士学位。
- Frank Fischer,has more than 40 years of senior management experience in the medical device industry. He co-founded NeuroPace in December 1997, led the company as its President and Chief Executive Officer from January 2000 through July 2019, served on its Board of Directors since inception and is currently Chairman of the Board. Prior to joining NeuroPace, Mr. Fischer was President and Chief Executive Officer of Heartport, Inc., a cardiac surgery company, from May 1998 until September 1999 and served on Heartport's Board of Directors. Previously, Mr. Fischer was President and Chief Executive Officer and a director of Ventritex, Inc., a company that pioneered implantable cardiac defibrillators, from July 1987 until the sale of the company to St. Jude Medical, Inc. in 1997. Before joining Ventritex, he held various management positions at Cordis Corporation from 1977 to 1987 in the cardiac and neurosurgical device areas, serving most recently as President of the Implantable Products Division. Currently he is a member of the Board of Directors of Nevro, Inc., the Board of Trustees of both Rensselaer Polytechnic Institute and Babson College as well as the Board of Directors of the Epilepsy Foundation of America. Mr. Fischer holds B.S.M.E. and M.S. in Management degrees from Rensselaer Polytechnic Institute.
- Greg Garfield
-
Greg Garfield自2016年9月起担任我们的董事会成员。自2016年3月以来，Garfield先生一直担任投资基金KCK-US，Inc.的高级董事总经理。在加入KCK-US之前，Garfield先生从2006年到2011年担任Acclarent，Inc.（一家医疗设备公司）的首席运营官and General Counsel。Garfield先生自2016年6月起担任医疗器械公司Mainstream Medical plc的董事会成员，并在其他几家私人公司的董事会任职。加菲尔德先生曾于2013年至2016年10月担任梦百合技术解决方案公司SemlerScientific，Inc.的董事。Garfield先生在加州理工大学（California Polytechnic State University）获得学士学位，在太平洋大学（University of the Pacific）麦乔治法学院（McGeorge School of Law）获得法学博士学位。
Greg Garfield has served as a member of our board of directors since September 2016. Since March 2016 Mr. Garfield has served as Senior Managing Director at KCK-US, Inc., an investment fund. Prior to KCK-US, Inc., Mr. Garfield served as Chief Operating Officer and General Counsel at Acclarent, Inc., a medical device company from 2006 to 2011. Mr. Garfield has served on the board of directors of Mainstay Medical plc, a medical device company, since June 2016 and serves on the boards of directors of several other private companies. Mr. Garfield previously served as a director of Semler Scientific, Inc., a healthcare technology solutions company, from 2013 until October 2016. Mr. Garfield earned a B.S. from California Polytechnic State University and a J.D. from McGeorge School of Law, University of the Pacific. - Greg Garfield自2016年9月起担任我们的董事会成员。自2016年3月以来，Garfield先生一直担任投资基金KCK-US，Inc.的高级董事总经理。在加入KCK-US之前，Garfield先生从2006年到2011年担任Acclarent，Inc.（一家医疗设备公司）的首席运营官and General Counsel。Garfield先生自2016年6月起担任医疗器械公司Mainstream Medical plc的董事会成员，并在其他几家私人公司的董事会任职。加菲尔德先生曾于2013年至2016年10月担任梦百合技术解决方案公司SemlerScientific，Inc.的董事。Garfield先生在加州理工大学（California Polytechnic State University）获得学士学位，在太平洋大学（University of the Pacific）麦乔治法学院（McGeorge School of Law）获得法学博士学位。
- Greg Garfield has served as a member of our board of directors since September 2016. Since March 2016 Mr. Garfield has served as Senior Managing Director at KCK-US, Inc., an investment fund. Prior to KCK-US, Inc., Mr. Garfield served as Chief Operating Officer and General Counsel at Acclarent, Inc., a medical device company from 2006 to 2011. Mr. Garfield has served on the board of directors of Mainstay Medical plc, a medical device company, since June 2016 and serves on the boards of directors of several other private companies. Mr. Garfield previously served as a director of Semler Scientific, Inc., a healthcare technology solutions company, from 2013 until October 2016. Mr. Garfield earned a B.S. from California Polytechnic State University and a J.D. from McGeorge School of Law, University of the Pacific.
- Nael Karim Kassar
-
Nael Karim Kassar自2016年9月起担任我们的董事会成员。自2018年4月以来，Kassar先生一直担任私人家族办公室投资基金KCK Ltd.的首席执行官。Kassar先生于2011年联合创立了KCK Ltd.，并自那时起担任执行董事。Kassar先生在伦敦帝国理工学院（Imperial College London）获得纯数学学士学位，并在剑桥大学（Cambridge University）获得数学高级研究硕士学位。
Nael Karim Kassar has served as a member of our board of directors since September 2016. Since April 2018 Mr. Kassar has served as Chief Executive Officer at KCK Ltd., a private family office investment fund. Mr. Kassar co-founded KCK Ltd. in 2011 and has served as an executive director since that time. Mr. Kassar earned a B.A. in Pure Mathematics from Imperial College London and an M.A. in Advanced Studies in Mathematics from Cambridge University. - Nael Karim Kassar自2016年9月起担任我们的董事会成员。自2018年4月以来，Kassar先生一直担任私人家族办公室投资基金KCK Ltd.的首席执行官。Kassar先生于2011年联合创立了KCK Ltd.，并自那时起担任执行董事。Kassar先生在伦敦帝国理工学院（Imperial College London）获得纯数学学士学位，并在剑桥大学（Cambridge University）获得数学高级研究硕士学位。
- Nael Karim Kassar has served as a member of our board of directors since September 2016. Since April 2018 Mr. Kassar has served as Chief Executive Officer at KCK Ltd., a private family office investment fund. Mr. Kassar co-founded KCK Ltd. in 2011 and has served as an executive director since that time. Mr. Kassar earned a B.A. in Pure Mathematics from Imperial College London and an M.A. in Advanced Studies in Mathematics from Cambridge University.
- Rakhi Kumar
-
Rakhi Kumar于2021年4月被任命为我们的董事会成员，在本招股说明书所包含的注册声明生效之前立即生效。自2018年6月以来，Kumar女士一直担任生物制药公司Roivant Sciences的首席会计官，领导Roivant的会计和财务运营以及相关的内部控制职能。Kumar女士于2015年9月加入Roivant，此前曾于2016年12月至2018年6月担任Vice President，财务和外部报告，并于2015年9月至2016年12月担任高级总监。在加入Roivant之前，Kumar女士于2013年6月至2015年9月在The Medicines Company任职，负责外部报告以及公司和技术会计。在职业生涯早期，Kumar女士在安永会计师事务所（Ernst and Young）的保证服务部门任职。Kumar女士在哈特福德大学（University of Hartford）获得会计与税务硕士学位。她是一名注册会计师。
Rakhi Kumar was appointed as a member of our board of directors in April 2021 effective immediately prior to the effectiveness of the registration statement of which this prospectus is a part. Since June 2018 Ms. Kumar has served as Chief Accounting Officer at Roivant Sciences, a biopharmaceutical company, where she leads Roivant’s accounting and financial operations and related internal controls functions. Ms. Kumar joined Roivant in September 2015 previously serving as Vice President, Finance and External Reporting, from December 2016 to June 2018 and as Senior Director, from September 2015 to December 2016. Prior to joining Roivant, Ms. Kumar was with The Medicines Company, from June 2013 to September 2015 where she was responsible for external reporting and corporate and technical accounting. Earlier in her career, Ms. Kumar was in the assurance services at Ernst and Young. Ms. Kumar earned an M.S in Accounting and Taxation from the University of Hartford. She is a certified public accountant. - Rakhi Kumar于2021年4月被任命为我们的董事会成员，在本招股说明书所包含的注册声明生效之前立即生效。自2018年6月以来，Kumar女士一直担任生物制药公司Roivant Sciences的首席会计官，领导Roivant的会计和财务运营以及相关的内部控制职能。Kumar女士于2015年9月加入Roivant，此前曾于2016年12月至2018年6月担任Vice President，财务和外部报告，并于2015年9月至2016年12月担任高级总监。在加入Roivant之前，Kumar女士于2013年6月至2015年9月在The Medicines Company任职，负责外部报告以及公司和技术会计。在职业生涯早期，Kumar女士在安永会计师事务所（Ernst and Young）的保证服务部门任职。Kumar女士在哈特福德大学（University of Hartford）获得会计与税务硕士学位。她是一名注册会计师。
- Rakhi Kumar was appointed as a member of our board of directors in April 2021 effective immediately prior to the effectiveness of the registration statement of which this prospectus is a part. Since June 2018 Ms. Kumar has served as Chief Accounting Officer at Roivant Sciences, a biopharmaceutical company, where she leads Roivant’s accounting and financial operations and related internal controls functions. Ms. Kumar joined Roivant in September 2015 previously serving as Vice President, Finance and External Reporting, from December 2016 to June 2018 and as Senior Director, from September 2015 to December 2016. Prior to joining Roivant, Ms. Kumar was with The Medicines Company, from June 2013 to September 2015 where she was responsible for external reporting and corporate and technical accounting. Earlier in her career, Ms. Kumar was in the assurance services at Ernst and Young. Ms. Kumar earned an M.S in Accounting and Taxation from the University of Hartford. She is a certified public accountant.
- Evan Norton
-
Evan Norton自2020年8月起担任我们的董事会成员。自2019年11月以来，诺顿先生一直担任AccelMed Partners（一家专注于医疗设备和医疗技术的私募股权公司）的普通合伙人。自2016年9月起，Norton先生还担任Northwestern University-Kellogg School Management兼职讲师。2014年至2019年11月，诺顿先生担任Abbot Labs的投资基金和全资子公司Abbot Ventures的风险投资部门Vice President，并于2013年至2014年担任风险投资董事总经理。Norton先生在德州农工大学（Texas A&M University）获得工商管理学士学位，并在西北大学凯洛格管理学院（Northwestern University，Kellogg School of Management）获得工商管理硕士学位。
Evan Norton,is Virax Biolabs Group Limited independent Director. Since December 2019, Mr. Norton has been a managing partner at Ballast Capital LLC, a private equity firm. Since September 2016, Mr. Norton has been an adjunct lecturer at Kellogg School of Management of Northwestern University. From November 2019 to May 2021, Mr. Norton served a general partner of Accelmed Partners II L.P., a private equity firm focused on investments in commercial stage Healthtech companies. From January 2010 to November 2019, Mr. Norton served as a director of venture investments and subsequently as managing director of Abbott Laboratories, with his final position as divisional vice president of venture investments of Abbott Laboratories (NYSE: ABT), a medical devices and health care company which provides pharmaceuticals and health care products and services. From 2007 to 2010, Mr. Norton served as a principal of Onset Ventures, a private equity firm which provides early-stage venture capital in the areas of information technology and medical. From 2006 to 2007, Mr. Norton served as a marketing manager of Lifescan, Inc., a subsidiary of Johnson & Johnson (NYSE: JNJ) which focuses on manufacturing products on the diabetes market, specifically blood glucose monitoring systems. From 2002 to 2003, Mr. Norton served a product manager of Stryker Corporation (NYSE: SYK), a medical technologies corporation. From 1998 to 2000, Mr. Norton served as an investment banking associate of JPMorgan Chase & Co. (NYSE: JPM), an investment bank and financial services holding company. From 1996 to 1998, Mr. Norton served as a management consultant in the consulting department of PricewaterhouseCoopers LLP, a public accounting company. Mr. Norton received a master of business administration's degree from Northwestern University and a bachelor's degree in business administration in finance from Texas A&M University in 1996 and 2002, respectively. - Evan Norton自2020年8月起担任我们的董事会成员。自2019年11月以来，诺顿先生一直担任AccelMed Partners（一家专注于医疗设备和医疗技术的私募股权公司）的普通合伙人。自2016年9月起，Norton先生还担任Northwestern University-Kellogg School Management兼职讲师。2014年至2019年11月，诺顿先生担任Abbot Labs的投资基金和全资子公司Abbot Ventures的风险投资部门Vice President，并于2013年至2014年担任风险投资董事总经理。Norton先生在德州农工大学（Texas A&M University）获得工商管理学士学位，并在西北大学凯洛格管理学院（Northwestern University，Kellogg School of Management）获得工商管理硕士学位。
- Evan Norton,is Virax Biolabs Group Limited independent Director. Since December 2019, Mr. Norton has been a managing partner at Ballast Capital LLC, a private equity firm. Since September 2016, Mr. Norton has been an adjunct lecturer at Kellogg School of Management of Northwestern University. From November 2019 to May 2021, Mr. Norton served a general partner of Accelmed Partners II L.P., a private equity firm focused on investments in commercial stage Healthtech companies. From January 2010 to November 2019, Mr. Norton served as a director of venture investments and subsequently as managing director of Abbott Laboratories, with his final position as divisional vice president of venture investments of Abbott Laboratories (NYSE: ABT), a medical devices and health care company which provides pharmaceuticals and health care products and services. From 2007 to 2010, Mr. Norton served as a principal of Onset Ventures, a private equity firm which provides early-stage venture capital in the areas of information technology and medical. From 2006 to 2007, Mr. Norton served as a marketing manager of Lifescan, Inc., a subsidiary of Johnson & Johnson (NYSE: JNJ) which focuses on manufacturing products on the diabetes market, specifically blood glucose monitoring systems. From 2002 to 2003, Mr. Norton served a product manager of Stryker Corporation (NYSE: SYK), a medical technologies corporation. From 1998 to 2000, Mr. Norton served as an investment banking associate of JPMorgan Chase & Co. (NYSE: JPM), an investment bank and financial services holding company. From 1996 to 1998, Mr. Norton served as a management consultant in the consulting department of PricewaterhouseCoopers LLP, a public accounting company. Mr. Norton received a master of business administration's degree from Northwestern University and a bachelor's degree in business administration in finance from Texas A&M University in 1996 and 2002, respectively.
- Renee Ryan
-
Renee Ryan，2013年起，担任本公司董事。自2019年8月以来，Ryan女士一直担任医疗技术公司Cala Health，Inc.的首席执行官。2011年至2019年8月，Ryan女士担任强生公司旗下风险投资部门强生公司Development Corp.的投资Vice President。Ryan从2008年到2011年担任Robert W.Baird&Co.（一家私募股权公司和金融服务公司）总经理。
Renee Ryan has served as a member of our board of directors since 2013. Since August 2019 Ms. Ryan has served as Chief Executive Officer at Cala Health, Inc., a medical technology company. From 2011 to August 2019 Ms. Ryan served as Vice President, Investments, at Johnson & Johnson Development Corp., the venture investing arm of Johnson & Johnson. From 2008 to 2011 Ms. Ryan served as Managing Director at Robert W. Baird & Co., a private equity firm and financial services company. - Renee Ryan，2013年起，担任本公司董事。自2019年8月以来，Ryan女士一直担任医疗技术公司Cala Health，Inc.的首席执行官。2011年至2019年8月，Ryan女士担任强生公司旗下风险投资部门强生公司Development Corp.的投资Vice President。Ryan从2008年到2011年担任Robert W.Baird&Co.（一家私募股权公司和金融服务公司）总经理。
- Renee Ryan has served as a member of our board of directors since 2013. Since August 2019 Ms. Ryan has served as Chief Executive Officer at Cala Health, Inc., a medical technology company. From 2011 to August 2019 Ms. Ryan served as Vice President, Investments, at Johnson & Johnson Development Corp., the venture investing arm of Johnson & Johnson. From 2008 to 2011 Ms. Ryan served as Managing Director at Robert W. Baird & Co., a private equity firm and financial services company.
- Michael Favet
-
Michael Favet自2019年7月起担任我们的总裁兼首席执行官，自2016年9月起担任我们的董事会成员。从2016年6月至2019年7月，Favet先生担任投资基金KCK-US，Inc.的董事总经理，负责战略投资和为投资组合公司提供建议，并于2018年10月至2019年7月担任我们的首席商务官。2015年至2017年1月，他曾担任Advanced Cardiac Therapeutics，Inc.（医疗设备公司）的首席运营官，在那里他负责监管运营。从2012年到2015年，Favet先生担任Sonitus Medical Inc.的首席运营官，这是一家医疗设备公司。Favet先生在伊利诺伊大学（University of Illinois）获得机械工程学士学位，在明尼苏达大学（University of Minnesota）获得工商管理硕士学位。
Michael Favet has served as our President and Chief Executive Officer since July 2019 and has served as a member of our board of directors since September 2016. From June 2016 to July 2019 Mr. Favet served as Managing Director at KCK-US, Inc., an investment fund, where he was responsible for strategic investments and advising portfolio companies, and also acted as our Chief Commercial Officer from October 2018 to July 2019. From 2015 to January 2017 Mr. Favet served as Chief Operating Officer at Advanced Cardiac Therapeutics, Inc., a medical device company, where he was responsible for overseeing operations. From 2012 to 2015 Mr. Favet served as Chief Operating Officer at Sonitus Medical Inc., a medical device company. Mr. Favet earned a B.S. in Mechanical Engineering from the University of Illinois and an M.B.A. from the University of Minnesota. - Michael Favet自2019年7月起担任我们的总裁兼首席执行官，自2016年9月起担任我们的董事会成员。从2016年6月至2019年7月，Favet先生担任投资基金KCK-US，Inc.的董事总经理，负责战略投资和为投资组合公司提供建议，并于2018年10月至2019年7月担任我们的首席商务官。2015年至2017年1月，他曾担任Advanced Cardiac Therapeutics，Inc.（医疗设备公司）的首席运营官，在那里他负责监管运营。从2012年到2015年，Favet先生担任Sonitus Medical Inc.的首席运营官，这是一家医疗设备公司。Favet先生在伊利诺伊大学（University of Illinois）获得机械工程学士学位，在明尼苏达大学（University of Minnesota）获得工商管理硕士学位。
- Michael Favet has served as our President and Chief Executive Officer since July 2019 and has served as a member of our board of directors since September 2016. From June 2016 to July 2019 Mr. Favet served as Managing Director at KCK-US, Inc., an investment fund, where he was responsible for strategic investments and advising portfolio companies, and also acted as our Chief Commercial Officer from October 2018 to July 2019. From 2015 to January 2017 Mr. Favet served as Chief Operating Officer at Advanced Cardiac Therapeutics, Inc., a medical device company, where he was responsible for overseeing operations. From 2012 to 2015 Mr. Favet served as Chief Operating Officer at Sonitus Medical Inc., a medical device company. Mr. Favet earned a B.S. in Mechanical Engineering from the University of Illinois and an M.B.A. from the University of Minnesota.
- Rishi Gupta
-
Rishi Gupta，自2016年10月起担任Turnstone Biologics Corp.董事会成员。Gupta先生还担任其他几家生物技术和制药公司的董事会成员，包括自2016年7月起担任维罗纳制药 PLC（纳斯达克：VRNA）董事会成员，自2019年7月起担任Enliven Therapeutics（纳斯达克：ELVN）董事会成员。Gupta先生自2013年6月以来一直是医疗保健和生物技术投资公司OrbiMed Advisors的合伙人。古普塔拥有耶鲁大学法学院法学博士学位和哈佛大学生化科学学士学位。
Rishi Gupta,has served as a member of Turnstone Biologics Corp. board of directors since October 2016. Mr. Gupta also serves on the boards of directors of several other biotechnology and pharmaceutical companies, including serving as a member of the board of Verona Pharma PLC (Nasdaq: VRNA) since July 2016 and Enliven Therapeutics (Nasdaq: ELVN) since July 2019. Mr. Gupta has been a Partner at OrbiMed Advisors, a healthcare and biotechnology investment firm since June 2013. Mr. Gupta has a J.D. from the Yale Law School and an A.B. in biochemical sciences from Harvard College. - Rishi Gupta，自2016年10月起担任Turnstone Biologics Corp.董事会成员。Gupta先生还担任其他几家生物技术和制药公司的董事会成员，包括自2016年7月起担任维罗纳制药 PLC（纳斯达克：VRNA）董事会成员，自2019年7月起担任Enliven Therapeutics（纳斯达克：ELVN）董事会成员。Gupta先生自2013年6月以来一直是医疗保健和生物技术投资公司OrbiMed Advisors的合伙人。古普塔拥有耶鲁大学法学院法学博士学位和哈佛大学生化科学学士学位。
- Rishi Gupta,has served as a member of Turnstone Biologics Corp. board of directors since October 2016. Mr. Gupta also serves on the boards of directors of several other biotechnology and pharmaceutical companies, including serving as a member of the board of Verona Pharma PLC (Nasdaq: VRNA) since July 2016 and Enliven Therapeutics (Nasdaq: ELVN) since July 2019. Mr. Gupta has been a Partner at OrbiMed Advisors, a healthcare and biotechnology investment firm since June 2013. Mr. Gupta has a J.D. from the Yale Law School and an A.B. in biochemical sciences from Harvard College.
- Joseph Lacob
-
Joseph Lacob自1997年8月担任Align 公司董事，自1987年出任风险投资公司Kleiner Perkins Caufield & Byers （KPCB）合作伙伴。2011年， Lacob 收购了全美篮球协会Golden State勇士队。他现任 勇士队股东兼首席执行官。在1987年加入KPCB之前， Lacob是 FHP国际Cetus 公司 （现Chiron）行政经理，公司是一家医疗保健组织，同时也担任Booz, Allen & Hamilton 公司管理顾问。此前他任职于Orexigen 诊疗公司董事会成员，该公司是一家研究肥胖症治疗以及相关药物研发的生物制药公司。Lacob同时也是个人、家庭和小企业健康保险在线服务公司eHealth 股份有限公司董事会成员。
Joseph Lacob acquired The Golden State Warriors of the National Basketball Association in 2010 and is currently the Managing Partner and CEO of the Warriors. From 1987 to 2018 he was a partner of Kleiner Perkins Caufield & Byers KPCB, a venture capital firm. Prior to joining KPCB, Mr. Lacob was an executive with Cetus Corporation (now Chiron), FHP International, a health maintenance organization, and Booz, Allen & Hamilton, a management consulting firm.Mr. Lacob earned an M.B.A. from Stanford University, a Masters in Public Health from the University of California at Los Angeles and a B.S. in Biological Sciences from the University of California at Irvine. - Joseph Lacob自1997年8月担任Align 公司董事，自1987年出任风险投资公司Kleiner Perkins Caufield & Byers （KPCB）合作伙伴。2011年， Lacob 收购了全美篮球协会Golden State勇士队。他现任 勇士队股东兼首席执行官。在1987年加入KPCB之前， Lacob是 FHP国际Cetus 公司 （现Chiron）行政经理，公司是一家医疗保健组织，同时也担任Booz, Allen & Hamilton 公司管理顾问。此前他任职于Orexigen 诊疗公司董事会成员，该公司是一家研究肥胖症治疗以及相关药物研发的生物制药公司。Lacob同时也是个人、家庭和小企业健康保险在线服务公司eHealth 股份有限公司董事会成员。
- Joseph Lacob acquired The Golden State Warriors of the National Basketball Association in 2010 and is currently the Managing Partner and CEO of the Warriors. From 1987 to 2018 he was a partner of Kleiner Perkins Caufield & Byers KPCB, a venture capital firm. Prior to joining KPCB, Mr. Lacob was an executive with Cetus Corporation (now Chiron), FHP International, a health maintenance organization, and Booz, Allen & Hamilton, a management consulting firm.Mr. Lacob earned an M.B.A. from Stanford University, a Masters in Public Health from the University of California at Los Angeles and a B.S. in Biological Sciences from the University of California at Irvine.
- Joseph S. Lacob
-
Joseph S. Lacob，2004年1月起，他担任我公司董事会成员。1987年起，他担任风险投资公司Kleiner Perkins Caufield & Byers的合伙人。他目前是Align Technology, Inc.以及多家私人公司，包括Opthonix, Inc.和TherOx, Inc. 的董事会成员。过去5年多时间内，他担任eHealth, Inc.的董事会成员。他在加利福尼亚大学尔弯分校（University of California, Irvine）获得生物科学学士学位，在加利福尼亚大学洛杉矶分校（University of California, Los Angeles）获得公共卫生学硕士学位，在斯坦福大学商学研究院（Stanford Graduate School of Business）获得工商管理学硕士学位。
Joseph S. Lacob has served as a member of our board of directors since 1997. Since 2010 Mr. Lacob has served as Co-Executive Chairman and Chief Executive Officer of the Golden State Warriors. Mr. Lacob has served as a director of Align Technology, Inc. a global medical device company, since 1997. Mr. Lacob earned a B.S. from the University of California, Irvine, an M.P.H. from the University of California, Los Angeles, and an M.B.A from the Stanford Graduate School of Business. - Joseph S. Lacob，2004年1月起，他担任我公司董事会成员。1987年起，他担任风险投资公司Kleiner Perkins Caufield & Byers的合伙人。他目前是Align Technology, Inc.以及多家私人公司，包括Opthonix, Inc.和TherOx, Inc. 的董事会成员。过去5年多时间内，他担任eHealth, Inc.的董事会成员。他在加利福尼亚大学尔弯分校（University of California, Irvine）获得生物科学学士学位，在加利福尼亚大学洛杉矶分校（University of California, Los Angeles）获得公共卫生学硕士学位，在斯坦福大学商学研究院（Stanford Graduate School of Business）获得工商管理学硕士学位。
- Joseph S. Lacob has served as a member of our board of directors since 1997. Since 2010 Mr. Lacob has served as Co-Executive Chairman and Chief Executive Officer of the Golden State Warriors. Mr. Lacob has served as a director of Align Technology, Inc. a global medical device company, since 1997. Mr. Lacob earned a B.S. from the University of California, Irvine, an M.P.H. from the University of California, Los Angeles, and an M.B.A from the Stanford Graduate School of Business.
高管简历
中英对照 | 中文 | 英文- Michael Favet
Michael Favet自2019年7月起担任我们的总裁兼首席执行官，自2016年9月起担任我们的董事会成员。从2016年6月至2019年7月，Favet先生担任投资基金KCK-US，Inc.的董事总经理，负责战略投资和为投资组合公司提供建议，并于2018年10月至2019年7月担任我们的首席商务官。2015年至2017年1月，他曾担任Advanced Cardiac Therapeutics，Inc.（医疗设备公司）的首席运营官，在那里他负责监管运营。从2012年到2015年，Favet先生担任Sonitus Medical Inc.的首席运营官，这是一家医疗设备公司。Favet先生在伊利诺伊大学（University of Illinois）获得机械工程学士学位，在明尼苏达大学（University of Minnesota）获得工商管理硕士学位。
Michael Favet has served as our President and Chief Executive Officer since July 2019 and has served as a member of our board of directors since September 2016. From June 2016 to July 2019 Mr. Favet served as Managing Director at KCK-US, Inc., an investment fund, where he was responsible for strategic investments and advising portfolio companies, and also acted as our Chief Commercial Officer from October 2018 to July 2019. From 2015 to January 2017 Mr. Favet served as Chief Operating Officer at Advanced Cardiac Therapeutics, Inc., a medical device company, where he was responsible for overseeing operations. From 2012 to 2015 Mr. Favet served as Chief Operating Officer at Sonitus Medical Inc., a medical device company. Mr. Favet earned a B.S. in Mechanical Engineering from the University of Illinois and an M.B.A. from the University of Minnesota.- Michael Favet自2019年7月起担任我们的总裁兼首席执行官，自2016年9月起担任我们的董事会成员。从2016年6月至2019年7月，Favet先生担任投资基金KCK-US，Inc.的董事总经理，负责战略投资和为投资组合公司提供建议，并于2018年10月至2019年7月担任我们的首席商务官。2015年至2017年1月，他曾担任Advanced Cardiac Therapeutics，Inc.（医疗设备公司）的首席运营官，在那里他负责监管运营。从2012年到2015年，Favet先生担任Sonitus Medical Inc.的首席运营官，这是一家医疗设备公司。Favet先生在伊利诺伊大学（University of Illinois）获得机械工程学士学位，在明尼苏达大学（University of Minnesota）获得工商管理硕士学位。
- Michael Favet has served as our President and Chief Executive Officer since July 2019 and has served as a member of our board of directors since September 2016. From June 2016 to July 2019 Mr. Favet served as Managing Director at KCK-US, Inc., an investment fund, where he was responsible for strategic investments and advising portfolio companies, and also acted as our Chief Commercial Officer from October 2018 to July 2019. From 2015 to January 2017 Mr. Favet served as Chief Operating Officer at Advanced Cardiac Therapeutics, Inc., a medical device company, where he was responsible for overseeing operations. From 2012 to 2015 Mr. Favet served as Chief Operating Officer at Sonitus Medical Inc., a medical device company. Mr. Favet earned a B.S. in Mechanical Engineering from the University of Illinois and an M.B.A. from the University of Minnesota.
- Martha Morrell
Martha Morrell自2004年以来担任我们的首席医疗官。Morrell博士还从2004年开始担任斯坦福大学（Stanford University）的神经学临床教授。Morrell博士之前从1998年到2004年担任哥伦比亚大学临床神经学Caitlin Tynan Doyle教授和纽约长老会医院哥伦比亚综合癫痫中心主任。在此之前，Morrell博士从1990年到1998年在斯坦福大学医学院（Stanford University School of Medicine）的教员和斯坦福综合癫痫中心（Stanford Comprehensive癫痫中心）的主任任职。Morrell博士在巴纳德学院（Barnard College）获得学士学位，在斯坦福大学医学院（Stanford University School of Medicine）获得硕士学位。
Martha Morrell has served as our Chief Medical Officer since 2004. Dr. Morrell has also served as a Clinical Professor of Neurology at Stanford University since 2004. Dr. Morrell previously served as the Caitlin Tynan Doyle Professor of Clinical Neurology at Columbia University and Director of the Columbia Comprehensive Epilepsy Center at New York Presbyterian Hospital from 1998 to 2004. Prior to that, Dr. Morrell served on the faculty of the Stanford University School of Medicine and as the Director of the Stanford Comprehensive Epilepsy Center from 1990 to 1998. Dr. Morrell earned a B.A. from Barnard College and an M.D. from the Stanford University School of Medicine.- Martha Morrell自2004年以来担任我们的首席医疗官。Morrell博士还从2004年开始担任斯坦福大学（Stanford University）的神经学临床教授。Morrell博士之前从1998年到2004年担任哥伦比亚大学临床神经学Caitlin Tynan Doyle教授和纽约长老会医院哥伦比亚综合癫痫中心主任。在此之前，Morrell博士从1990年到1998年在斯坦福大学医学院（Stanford University School of Medicine）的教员和斯坦福综合癫痫中心（Stanford Comprehensive癫痫中心）的主任任职。Morrell博士在巴纳德学院（Barnard College）获得学士学位，在斯坦福大学医学院（Stanford University School of Medicine）获得硕士学位。
- Martha Morrell has served as our Chief Medical Officer since 2004. Dr. Morrell has also served as a Clinical Professor of Neurology at Stanford University since 2004. Dr. Morrell previously served as the Caitlin Tynan Doyle Professor of Clinical Neurology at Columbia University and Director of the Columbia Comprehensive Epilepsy Center at New York Presbyterian Hospital from 1998 to 2004. Prior to that, Dr. Morrell served on the faculty of the Stanford University School of Medicine and as the Director of the Stanford Comprehensive Epilepsy Center from 1990 to 1998. Dr. Morrell earned a B.A. from Barnard College and an M.D. from the Stanford University School of Medicine.
- Rebecca Kuhn
Rebecca Kuhn，2000年起，担任本公司的首席财务官、Vice President、财务与管理。从1992年到2000年，Kuhn女士担任越来越重要的职务，最近担任Heartport，Inc.的财务主管兼财务总监，该公司是一家医疗设备公司。Kuhn女士在俄亥俄州立大学（Ohio State University）获得工商管理学士学位，在斯坦福大学商学院（Graduate School of Business）获得工商管理硕士学位。
Rebecca Kuhn has served as our Chief Financial Officer and Vice President, Finance and Administration since 2000. From 1992 to 2000 Ms. Kuhn served in roles of increasing responsibility, most recently as Treasurer and Director of Finance at Heartport, Inc., a medical device company. Ms. Kuhn earned a B.S. in Business Administration from The Ohio State University and an M.B.A. from the Graduate School of Business at Stanford University.- Rebecca Kuhn，2000年起，担任本公司的首席财务官、Vice President、财务与管理。从1992年到2000年，Kuhn女士担任越来越重要的职务，最近担任Heartport，Inc.的财务主管兼财务总监，该公司是一家医疗设备公司。Kuhn女士在俄亥俄州立大学（Ohio State University）获得工商管理学士学位，在斯坦福大学商学院（Graduate School of Business）获得工商管理硕士学位。
- Rebecca Kuhn has served as our Chief Financial Officer and Vice President, Finance and Administration since 2000. From 1992 to 2000 Ms. Kuhn served in roles of increasing responsibility, most recently as Treasurer and Director of Finance at Heartport, Inc., a medical device company. Ms. Kuhn earned a B.S. in Business Administration from The Ohio State University and an M.B.A. from the Graduate School of Business at Stanford University.
- Irina Ridley
Irina Ridley自2020年11月起担任我们的总法律顾问兼公司秘书。Ridley女士此前曾于2018年8月至2020年11月担任精密医疗公司MyriadGenetics，Inc.的首席法律顾问，负责公司法律事务。2016年8月至2018年8月，她担任基因检测公司Counsyl Inc.的副总法律顾问兼隐私官，在该公司被MyriadGenetics，Inc.收购之前，她负责公司法律事务。从2014年到2016年8月，她曾担任Omada Health公司（数字健康公司）的合规和隐私官，在那里她曾担任第一律师，并负责构建Omada Health公司的合规和隐私计划。在此之前，Ridley从2011年到2014年在管理咨询公司任职，在Deloitte Tax，LLP和普华永道会计师事务所（PricewaterhouseCoopers）担任越来越重要的职务。Ridley女士自2016年7月起担任奥尔巴尼法学院校友董事会成员，此前于2016年5月至2017年10月担任Women in Security and Privacy董事会成员。Ridley女士在伦斯勒理工学院（Rensselaer Polytechnic Institute）获得学士学位和工商管理硕士学位，并在联合大学奥尔巴尼法学院（Albany Law School of Union University）获得法学博士学位。
Irina Ridley has served as our General Counsel and Corporate Secretary since November 2020. Ms. Ridley previously served as Chief Counsel at Myriad Genetics, Inc., a precision medicine company, from August 2018 to November 2020 where she was responsible for corporate legal matters. From August 2016 to August 2018 she served as Associate General Counsel and Privacy Officer at Counsyl Inc., a genetic testing company, where prior to its acquisition by Myriad Genetics, Inc., she was responsible for corporate legal matters. From 2014 to August 2016 she served as Compliance and Privacy Officer at Omada Health, a digital health company, where she was the first attorney and was responsible for building out Omada Health’s compliance and privacy programs. Prior to that, from 2011 to 2014 Ms. Ridley worked in management consulting, serving in roles of increasing responsibility at Deloitte Tax, LLP, and PricewaterhouseCoopers. Ms. Ridley has served on the Alumni Board of Directors of Albany Law School since July 2016 and previously served on the Board of Directors of Women in Security and Privacy from May 2016 to October 2017. Ms. Ridley earned a B.S. and an M.B.A. from the Rensselaer Polytechnic Institute and a J.D. from Albany Law School of Union University.- Irina Ridley自2020年11月起担任我们的总法律顾问兼公司秘书。Ridley女士此前曾于2018年8月至2020年11月担任精密医疗公司MyriadGenetics，Inc.的首席法律顾问，负责公司法律事务。2016年8月至2018年8月，她担任基因检测公司Counsyl Inc.的副总法律顾问兼隐私官，在该公司被MyriadGenetics，Inc.收购之前，她负责公司法律事务。从2014年到2016年8月，她曾担任Omada Health公司（数字健康公司）的合规和隐私官，在那里她曾担任第一律师，并负责构建Omada Health公司的合规和隐私计划。在此之前，Ridley从2011年到2014年在管理咨询公司任职，在Deloitte Tax，LLP和普华永道会计师事务所（PricewaterhouseCoopers）担任越来越重要的职务。Ridley女士自2016年7月起担任奥尔巴尼法学院校友董事会成员，此前于2016年5月至2017年10月担任Women in Security and Privacy董事会成员。Ridley女士在伦斯勒理工学院（Rensselaer Polytechnic Institute）获得学士学位和工商管理硕士学位，并在联合大学奥尔巴尼法学院（Albany Law School of Union University）获得法学博士学位。
- Irina Ridley has served as our General Counsel and Corporate Secretary since November 2020. Ms. Ridley previously served as Chief Counsel at Myriad Genetics, Inc., a precision medicine company, from August 2018 to November 2020 where she was responsible for corporate legal matters. From August 2016 to August 2018 she served as Associate General Counsel and Privacy Officer at Counsyl Inc., a genetic testing company, where prior to its acquisition by Myriad Genetics, Inc., she was responsible for corporate legal matters. From 2014 to August 2016 she served as Compliance and Privacy Officer at Omada Health, a digital health company, where she was the first attorney and was responsible for building out Omada Health’s compliance and privacy programs. Prior to that, from 2011 to 2014 Ms. Ridley worked in management consulting, serving in roles of increasing responsibility at Deloitte Tax, LLP, and PricewaterhouseCoopers. Ms. Ridley has served on the Alumni Board of Directors of Albany Law School since July 2016 and previously served on the Board of Directors of Women in Security and Privacy from May 2016 to October 2017. Ms. Ridley earned a B.S. and an M.B.A. from the Rensselaer Polytechnic Institute and a J.D. from Albany Law School of Union University.